See more : TRU Precious Metals Corp. (TRU.V) Income Statement Analysis – Financial Results
Complete financial analysis of Editas Medicine, Inc. (EDIT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Editas Medicine, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Guerrilla RF, Inc. (GUER) Income Statement Analysis – Financial Results
- K.C.P. Sugar and Industries Corporation Limited (KCPSUGIND.NS) Income Statement Analysis – Financial Results
- Bank of Ningbo Co., Ltd. (002142.SZ) Income Statement Analysis – Financial Results
- Flag Ship Acquisition Corp. Unit (FSHPU) Income Statement Analysis – Financial Results
- Asia Orient Holdings Limited (0214.HK) Income Statement Analysis – Financial Results
Editas Medicine, Inc. (EDIT)
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 78.12M | 19.71M | 25.54M | 90.73M | 20.53M | 31.94M | 13.73M | 6.05M | 1.63M | 0.00 | 0.00 |
| Cost of Revenue | 177.65M | 6.34M | 5.05M | 158.00M | 96.90M | 90.65M | 83.16M | 56.98M | 18.85M | 5.07M | 1.59M |
| Gross Profit | -99.53M | 13.38M | 20.49M | -67.26M | -76.37M | -58.72M | -69.43M | -50.93M | -17.22M | -5.07M | -1.59M |
| Gross Profit Ratio | -127.40% | 67.85% | 80.22% | -74.13% | -371.96% | -183.85% | -505.76% | -841.33% | -1,056.91% | 0.00% | 0.00% |
| Research & Development | 177.65M | 174.96M | 142.51M | 158.00M | 96.90M | 90.65M | 83.16M | 56.98M | 18.85M | 5.07M | 1.59M |
| General & Administrative | 69.65M | 70.70M | 76.18M | 67.58M | 64.56M | 55.01M | 50.50M | 46.26M | 18.10M | 7.65M | 3.63M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 69.65M | 70.70M | 76.18M | 67.58M | 64.56M | 55.01M | 50.50M | 46.26M | 18.10M | 7.65M | 3.63M |
| Other Expenses | 0.00 | 1.29M | -1.70M | 16.26M | -137.00K | 328.00K | 587.00K | -57.00K | -37.45M | -928.00K | 0.00 |
| Operating Expenses | 247.30M | 245.66M | 218.69M | 225.57M | 161.45M | 145.66M | 133.66M | 103.24M | 36.94M | 12.72M | 3.68M |
| Cost & Expenses | 247.30M | 245.66M | 218.69M | 225.57M | 161.45M | 145.66M | 133.66M | 103.24M | 36.94M | 12.72M | 5.27M |
| Interest Income | 17.57M | 4.23M | 2.34M | 2.61M | 7.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 4.23M | 0.00 | 0.00 | 0.00 | 0.00 | 978.00K | 0.00 | 143.00K | 34.00K | 0.00 |
| Depreciation & Amortization | 6.06M | 6.34M | 5.05M | 3.96M | 2.83M | 3.25M | 2.68M | 1.20M | 471.00K | 157.00K | 3.00K |
| EBITDA | -163.12M | -219.61M | -188.09M | -130.88M | -138.09M | -110.47M | -116.66M | -96.07M | -72.29M | -13.49M | -5.22M |
| EBITDA Ratio | -208.80% | -1,146.26% | -756.13% | -148.61% | -687.05% | -355.07% | -869.36% | -1,606.56% | -4,466.36% | 0.00% | 0.00% |
| Operating Income | -169.18M | -225.95M | -193.15M | -134.84M | -140.92M | -113.73M | -119.93M | -97.19M | -35.31M | -12.72M | -5.22M |
| Operating Income Ratio | -216.56% | -1,146.26% | -756.13% | -148.61% | -686.39% | -356.10% | -873.64% | -1,605.62% | -2,167.71% | 0.00% | 0.00% |
| Total Other Income/Expenses | 15.96M | 5.52M | 644.00K | 18.86M | 7.18M | 3.77M | -391.00K | 5.00K | -37.59M | -962.00K | -54.00K |
| Income Before Tax | -153.22M | -220.43M | -192.50M | -115.98M | -133.75M | -109.95M | -120.32M | -97.18M | -72.90M | -13.69M | -5.27M |
| Income Before Tax Ratio | -196.13% | -1,118.26% | -753.61% | -127.82% | -651.43% | -344.28% | -876.49% | -1,605.53% | -4,475.14% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -16.08M | -7.40M | -6.56M | -10.28M | -3.12M | -1.12M | -1.32M | -37.77M | -894.00K | 75.00K |
| Net Income | -153.22M | -204.35M | -185.11M | -109.41M | -123.47M | -109.95M | -120.32M | -97.18M | -72.90M | -13.69M | -5.35M |
| Net Income Ratio | -196.13% | -1,036.69% | -724.66% | -120.59% | -601.36% | -344.28% | -876.49% | -1,605.53% | -4,475.14% | 0.00% | 0.00% |
| EPS | -2.02 | -2.98 | -2.74 | -1.87 | -2.47 | -2.33 | -2.98 | -3.02 | -2.04 | -0.89 | -17.80 |
| EPS Diluted | -2.02 | -2.98 | -2.74 | -1.87 | -2.47 | -2.33 | -2.98 | -3.02 | -2.04 | -0.89 | -17.80 |
| Weighted Avg Shares Out | 75.97M | 68.66M | 67.62M | 58.61M | 49.98M | 47.10M | 40.32M | 32.22M | 35.70M | 15.44M | 300.48K |
| Weighted Avg Shares Out (Dil) | 75.97M | 68.66M | 67.62M | 58.61M | 49.98M | 47.10M | 40.32M | 32.22M | 35.70M | 15.44M | 300.48K |
Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas Medicine Announces First Quarter 2024 Results and Business Updates
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)
Source: https://incomestatements.info
Category: Stock Reports